Bioblast Pharma Ltd. CEO Colin Foster told BioWorld Today "it would not be unreasonable to think" that regulators could deem pivotal the upcoming phase IIb trial with trehalose in oculopharyngeal muscular dystrophy (OPMD), but the company doesn't count on that. "We're looking forward, recognizing that we [probably] have to do a phase III study," he said.